Statements (58)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:chemical_compound
|
| gptkbp:affiliated_with |
gptkb:ABC_University
DEF Hospital |
| gptkbp:animal_model |
mouse model
rat model |
| gptkbp:bioavailability |
high
|
| gptkbp:casnumber |
123456-78-9
|
| gptkbp:chemical_formula |
C12 H15 N3 O2
|
| gptkbp:class |
antineoplastic agent
|
| gptkbp:clinical_trial |
ongoing
Phase II Phase I |
| gptkbp:collaborations |
gptkb:international_collaboration
|
| gptkbp:composed_by |
gptkb:chemical_compound
|
| gptkbp:discovered_by |
gptkb:XYZ_Research_Institute
|
| gptkbp:dissolved |
soluble in DMSO
slightly soluble in water |
| gptkbp:funding |
private investment
government grant |
| gptkbp:future_prospects |
combination therapy
long-term effects biomarker identification patient stratification |
| https://www.w3.org/2000/01/rdf-schema#label |
SCG 004
|
| gptkbp:invention |
patented
|
| gptkbp:investment |
high demand
targeted therapies growing interest oncology drugs |
| gptkbp:lifespan |
4 hours
|
| gptkbp:mechanism_of_action |
inhibits cell proliferation
|
| gptkbp:notable_work |
low toxicity
promising results high efficacy |
| gptkbp:previous_name |
N-(4-(2-(4-(dimethylamino)phenyl)thiazol-4-yl)thiazol-2-yl)phenyl)acetamide
|
| gptkbp:project |
preclinical
|
| gptkbp:publication |
conference presentation
published in peer-reviewed journal patent application filed |
| gptkbp:regulatory_compliance |
under review
|
| gptkbp:related_products |
filed
|
| gptkbp:research_areas |
oncology
|
| gptkbp:route_of_administration |
oral
intravenous |
| gptkbp:safety_features |
monitored
|
| gptkbp:side_effect |
fatigue
headache nausea cardiovascular issues liver toxicity kidney toxicity |
| gptkbp:targets |
gptkb:VEGFR
gptkb:EGFR specific cancer cells |
| gptkbp:used_in |
pharmaceutical research
|
| gptkbp:weight |
233.27 g/mol
|
| gptkbp:bfsParent |
gptkb:SCG_003
|
| gptkbp:bfsLayer |
6
|